Korea Pharma Co., Ltd. (032300.KQ) Stock

032300.KQ logo

Korea Pharma Co., Ltd.

032300.KQSouth Korea
Healthcare

Company profile

Korea Pharma reported revenue of 87.60 billion KRW for fiscal year 2025, up 7.8% from fiscal year 2024. Our analysis of its filings shows revenue growing from 83.24 billion KRW in fiscal year 2023 to 87.60 billion KRW in fiscal year 2025, 2.6% a year on average.

What stands out

  • It reported a net loss of 2.64 billion KRW in fiscal year 2025, after a profit of 3.79 billion KRW in fiscal year 2024.
  • Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Korea Pharma Co., Ltd.

KOREA PHARMA Co., Ltd. produces pharmaceutical drugs. The company offers amino acid, antibiotic, antidotal, antiepileptic, antihistamine, anti-inflammatory, antimicrobial, antiplatelet, circulatory system, CNS, dermatological, endocrine, gastrointestinal, hepatic, hormonal, respiratory, sympathomimetic, skeltal muscle relaxants, and specialty drugs, as well as multivitamins, and vitamin B1, etc. KOREA PHARMA Co., Ltd. was founded in 1974 and is based in Seoul, South Korea.

Largest shareholders

  • Jae-Don Park25.12 %25.12%
  • Eun-Hee Park16.69 %16.69%
  • Yoon-seok Park13.75 %13.75%
  • Geun-hee Park7.152 %7.15%
  • Jin-woo Lee0.3796 %0.38%

Share of the company, as of September 25, 2026

Leadership

  • Eun-Hee Park — CEO & Director, 68
  • Yong-Ki Park — Chief Financial Officer, 64

How much revenue does Korea Pharma make?

Korea Pharma reported 87.60 billion KRW in revenue for fiscal year 2025, up 7.8% from 81.28 billion KRW in fiscal year 2024.

What companies are similar to Korea Pharma?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Handok Inc. (002390.KS), Dong Sung Bio Pharm.Co.,Ltd. (002210.KS), Withus Pharmaceutical Co.,LTD. (330350.KQ), Sinil Pharmaceutical Co., Ltd. (012790.KQ).

Has Korea Pharma made a profit in recent years?

Net income by fiscal year: FY2021, 6.37 billion KRW; FY2022, a loss of 1.12 billion KRW; FY2023, 83.76 million KRW; FY2024, 3.79 billion KRW; FY2025, a loss of 2.64 billion KRW. It reported a net loss in 2 of these 5 years.

How has Korea Pharma's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 79.58 billion KRW; FY2022, 81.03 billion KRW; FY2023, 83.24 billion KRW; FY2024, 81.28 billion KRW; FY2025, 87.60 billion KRW.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
HeadquartersSeoul, South Korea
ExchangeKOSDAQ
TimezoneAsia/Seoul (KST)

Contact & Links

Address
14, Teheran-ro 4-gil, Seoul, 06232
Phone
82 558 1277
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Korea Pharma Co., Ltd. (032300.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/032300.KQ

LinkedInLinkedInXXYouTubeYouTube